Pyxis Oncology (NASDAQ:PYXS) versus Nanobiotix (NASDAQ:NBTX) Head to Head Comparison

Pyxis Oncology (NASDAQ:PYXS) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Risk and Volatility

Pyxis Oncology has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares Pyxis Oncology and Nanobiotix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$16.15 million	5.86	-$77.33 million	($1.60)	-0.95
Nanobiotix	$39.18 million	31.87	-$73.73 million	N/A	N/A

Nanobiotix has higher revenue and earnings than Pyxis Oncology.

Profitability

This table compares Pyxis Oncology and Nanobiotix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-84.70%	-61.72%
Nanobiotix	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Pyxis Oncology and Nanobiotix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1	1	5	0	2.57
Nanobiotix	1	0	4	0	2.60

Pyxis Oncology presently has a consensus target price of $7.20, suggesting a potential upside of 373.68%. Nanobiotix has a consensus target price of $20.00, suggesting a potential downside of 22.48%. Given Pyxis Oncology’s higher probable upside, equities analysts plainly believe Pyxis Oncology is more favorable than Nanobiotix.

Insider and Institutional Ownership

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Nanobiotix beats Pyxis Oncology on 6 of the 11 factors compared between the two stocks.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.